Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

Trial Profile

Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Fenoldopam (Primary) ; Indometacin
  • Indications Acute kidney injury
  • Focus Pharmacodynamics
  • Acronyms Fenaki
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 15 Feb 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top